CONCLUSION
MDD, depressive symptoms
This phase 1 study of zuranolone in Japan demonstrated that all tested doses (≤30 mg) were well tolerated and that their PK profiles were not significantly affected by ethnicity or age. Plasma exposures of zuranolone were greater in the fed than the fasted state. Zuranolone 30 mg, but not 10 mg, enhanced low‐beta power. These findings lay the groundwork for future research into the efficacy of zuranolone on depressive symptoms and its safety in the Japanese population. The recently concluded phase 2 trial of zuranolone that assessed 20‐ and 30‐mg doses in a Japanese population with MDD will shed more light on its antidepressant effects and safety in this population.